Introduction
Herpes zoster is caused by a reactivation of a latent infection by varicella zoster virus (VZV) in either the spinal or trigeminal sensory ganglia. Initially, it manifests clinically as oedematous erythema and grouped vesicles with pain along the sensory nerve unilaterally. In some cases, the lesions may exhibit ulceration and necrosis with leucocytoclastic vasculitis in the upper dermis. 1 Acyclovir, administered either intravenously or orally, has been used in treatment and its efficacy has been confirmed clinically in patients with acute herpes zoster. 2 However, the presence of VZV antigens in the epidermis of patients with herpes zoster before and after administration of acyclovir has not been investigated immunohistochemically. The aim of this study was to determine the distribution of VZV antigens in herpetic lesions before and after acyclovir therapy by an immunohistochemical method utilizing antibodies to VZV, and to correlate the presence of VZV antigens with clinical manifestations of the disease. 
PATIENTS
Four patients (two men; two women; age range, 54 -71 years) with a clinical diagnosis of herpes zoster were selected for the study and admitted to a hospital ward. All of the patients gave their informed consent, and the study was approved by the hospital's Institutional Review Board.
Intravenous acyclovir therapy (750 mg/day) was commenced on admission and continued for 5 -7 days. None of the patients had renal disease or severe, life-threatening illnesses, and none was receiving immunosuppressive drugs such as cyclosporin or corticosteroids. However, one patient (No. 2) had a mixed connective tissue disease and necrotizing lymphadenitis, while another (No. 3) had chronic eczema. Four biopsy specimens were obtained from either erythematous or vesicular lesions before acyclovir administration and fixed with formalin. Following acyclovir therapy, a further four biopsy specimens were taken from the patients' erosive, ulcerative or pigmented lesions.
IMMUNOHISTOCHEMICAL METHODS
Formalin-fixed preparations were embedded in paraffin, cut into thin sections with microtome, and the paraffin removed with trypsin. Endogenous peroxidase was then removed with hydrogen peroxide and methanol, and the sample incubated with normal horse serum for 20 min followed by mouse anti-VZV antibody at 4°C overnight. 3 The VZV antibody was a monoclonal antibody to the nucleocapsid and glycoproteins of VZV. The sample was then incubated with biotinized anti-mouse antibodies (Vector, Burlingame, California, USA) at 37°C for 45 min and avidin-biotin complex (Vector) at 37°C for 45 min, and peroxidase stained with diaminobenzidine (Dojin Chemical, Kumamoto, Japan). Subsequently, the sample was counterstained with methyl green (Chroma, Stuttgart, Germany).
Results
In patient No. 1, a 71-year-old man, haemorrhagic vesicles, erosion and crusts were present in the area of the first branch of the trigeminal nerve before acyclovir treatment (Fig. 1) . A biopsy taken from the lesion on the left side of the forehead showed an intraepidermal vesicle with numerous lymphocytes. Immunohistochemical staining showed that VZV antigens were present in the keratinocytes and mononuclear cells of the intraepidermal vesicle (Fig. 2) . Following treatment with intravenous acyclovir 750 mg/day for 7 days, the vesicles disappeared and erosions, ulcers and necrotic crusts were observed (Fig. 3) . Immunohistochemical staining of a I Kurokawa, M Yamamoto, T Kurata VZV antigens before and after acyclovir treatment pigmentation and crusts (Fig. 7) . Immunohistochemical staining of a sample from the pigmented lesion showed no reaction to VZV antibody in the epidermis (Fig. 8) . In patient No. 4, a 64-year-old woman, immunohistochemical staining before acyclovir administration showed a positive reaction to VZV antibody in the blister roof and base in the epidermis (Fig. 9) . There was no positive reaction after acyclovir treatment, however (Fig. 10 ). 
Discussion
Acyclovir was introduced in 1977, 4 and has been shown to be clinically useful in the treatment of herpes zoster, 2 particularly when administration is begun within 3 days of the onset of symptoms. 4 Clinically, acyclovir reduces the times to final new lesion formation, loss of vesicles and full crusting. 5 In immunocompetent patients, intravenous acyclovir therapy significantly reduces viral shedding and hastens rash resolution. 2 However, an immunohistochemical study of the effect of acyclovir on VZV antigens in the epidermis in herpes zoster patients has not previously been performed. Some immunohistochemical studies documenting the presence of VZV antigen in herpes zoster lesions have, nevertheless, been reported. Based on clinical symptoms, Muraki et al. 6 classified herpes zoster into four stages: erythematous, vesicular, pustular and ulcerative. In the erythematous stage, VZV antigens were found only within ballooning cells in the epidermis. In the vesicular stage, VZV antigens were detected in the intraepidermal vesicles of all patients studied, while in the pustular stage they were observed in some necrotic or degenerated keratinocytes and multinucleated cells in the epidermis. In the ulcerative stage, VZV antigens were detected only at ulcer margins and around the hair shaft in two of seven patients. 6 In our study, VZV antigens were detected in the intraepidermal vesicles and in keratinocytes of the blister roof and base in all four patients studied prior to acyclovir administration. However, they were not found in the epidermis after 5 -7 days' treatment with acyclovir 750 mg/day intravenously. Thus, while VZV antigens were generally present in the epidermis in the vesicular stage, they were absent in the ulcerative, crusted or pigmented stage, and in this respect our findings are consistent with those of Muraki et al. 6 In a subsequent report, Muraki et al. 7 emphasized follicular involvement in herpes zoster in the early phase and in the pustular phase. In our study, the biopsy specimens from the herpetic lesions before and after acyclovir treatment did not always include follicles, and it was therefore impossible to evaluate and compare the presence of VZV antigens in hair follicles in our patients. Rather, we focused on the distribution of VZV antigens in the epidermis. Muraki et al. 6 have pointed out that VZV antigens are also present in fibroblasts, histiocytes and endothelial cells in the dermis. In other studies, VZV antigens have been demonstrated in herpes zoster lesions by immunofluorescence, 8 and an electron microscope study has detected VZV in fully developed vesicles. 9 In a study in which VZV was identified by culture methods, Nimura et al. 10 reported that acyclovir 4000 mg/day orally for 7 days shortened the time to disappearance of VZV in herpes zoster lesions in comparison with placebo. The time until disappearance of I Kurokawa, M Yamamoto, T Kurata VZV antigens before and after acyclovir treatment VZV was about 10 days in acyclovir-treated patients. In our study, VZV antigens were not found in epidermal lesions after 5 -7 days' treatment with intravenous acyclovir 750 mg/day. The difference between the two studies in the times until disappearance of VZV may be related to the higher serum concentration of acyclovir that is achieved with intravenous therapy, the different methods of detecting VZV, and the fact that our patients were hospitalized with bed rest.
In conclusion, we have shown in this immunohistochemical study that VZV antigens were no longer present in epidermal herpes zoster lesions after 5 -7 days' treatment with intravenous acyclovir.
For ethical reasons, the study was not a double-blind, controlled investigation and it was not possible, therefore, to determine whether the loss of VZV antigens was due to acyclovir or to a natural decrease over time.
Further controlled studies will therefore be necessary to compare the distribution of VZV antigens in acyclovir-treated patients with that in a placebo group to confirm the efficacy of acyclovir in hastening the loss of epidermal VZV antigens.
